This Nuclear Energy Stock Just Got a Big Government Boost. Should You Buy It Here?
Centrus Energy (LEU) shares inched up on Friday after the nuclear energy company secured an extension on its government contract to produce High-Assay, Low-Enriched Uranium (HALEU).
LEU's press release valued the one-year extension at about $110 million, adding that the Department of Energy (DOE) has the option to extend that contract for up to eight more years.
Dear Tesla Stock Fans, Mark Your Calendars for June 30
3 ETFs with Dividend Yields of 12% or Higher for Your Income Portfolio
This Options Tool Can Show You How to Trade Tesla Stock Ahead of Robotaxi Day
Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now!
Including today's gain, Centrus Energy stock is up more than 280% versus its low set in early April.
The HALEU contract extension is rather meaningful for Centrus Energy stock as it ensures continued visibility into future revenues.
Additionally, this government extension reinforces the clean energy firm's pivotal role in restoring the country's ability to enrich uranium (UXM25) as well.
With up to eight additional years of production still on the table, the DOE deal positions LEU as a long-term strategic partner in fueling next-generation nuclear reactors.
As global interest in clean, secure energy intensifies, partly due to rapidly increasing demand from AI – Maryland-based Centrus stands to benefit from both commercial and national security-driven demand for HALEU.
That makes LEU shares more attractive for long-term growth investors.
Despite its meteoric run in recent months, Evercore ISI analysts are convinced that Centrus Energy stock has further room to the upside.
Earlier this week, the investment firm reiterated its 'Outperform' rating on the clean energy stock and raised its price target to $205, which indicates potential upside of another 8.5% from current levels.
Evercore ISI remains positive on LEU shares mostly because Centrus is the only company that the Nuclear Regulatory Commission has licensed so far for HALEU production.
According to its analysts, the U.S. must 'unleash its advanced nuclear energy' to win the AI race.
Other Wall Street analysts are nowhere near as constructive on LEU stock as Evercore ISI since it's already pricing in a lot of the good news.
While the consensus rating on Centrus Energy remains at 'Strong Buy,' the mean target of about $157 indicates potential 'downside' of as much as 17% from here.
On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
This Nuclear Energy Stock Just Got a Big Government Boost. Should You Buy It Here?
Centrus Energy (LEU) shares inched up on Friday after the nuclear energy company secured an extension on its government contract to produce High-Assay, Low-Enriched Uranium (HALEU). LEU's press release valued the one-year extension at about $110 million, adding that the Department of Energy (DOE) has the option to extend that contract for up to eight more years. Dear Tesla Stock Fans, Mark Your Calendars for June 30 The 'Golden Era' for Tesla Starts June 22. Should You Buy TSLA Stock First? Nvidia Is Quickly Approaching a New Record High. Is It Too Late to Buy NVDA Stock? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Including today's gain, Centrus Energy stock is up more than 280% versus its low set in early April. The HALEU contract extension is rather meaningful for Centrus Energy stock as it ensures continued visibility into future revenues. Additionally, this government extension reinforces the clean energy firm's pivotal role in restoring the country's ability to enrich uranium (UXM25) as well. With up to eight additional years of production still on the table, the DOE deal positions LEU as a long-term strategic partner in fueling next-generation nuclear reactors. As global interest in clean, secure energy intensifies, partly due to rapidly increasing demand from AI – Maryland-based Centrus stands to benefit from both commercial and national security-driven demand for HALEU. That makes LEU shares more attractive for long-term growth investors. Despite its meteoric run in recent months, Evercore ISI analysts are convinced that Centrus Energy stock has further room to the upside. Earlier this week, the investment firm reiterated its 'Outperform' rating on the clean energy stock and raised its price target to $205, which indicates potential upside of another 8.5% from current levels. Evercore ISI remains positive on LEU shares mostly because Centrus is the only company that the Nuclear Regulatory Commission has licensed so far for HALEU production. According to its analysts, the U.S. must 'unleash its advanced nuclear energy' to win the AI race. Other Wall Street analysts are nowhere near as constructive on LEU stock as Evercore ISI since it's already pricing in a lot of the good news. While the consensus rating on Centrus Energy remains at 'Strong Buy,' the mean target of about $157 indicates potential 'downside' of as much as 17% from here. On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 hours ago
- Yahoo
Is Labcorp Holdings Stock Outperforming the Dow?
With a market cap of $21.9 billion, Labcorp Holdings Inc. (LH) provides laboratory services, aiding doctors, hospitals, pharmaceutical companies, researchers, and patients. Based in Burlington, North Carolina, the company operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. Companies worth $10 billion or more are typically referred to as "large-cap stocks." LH fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the diagnostics & research industry. 2 Outstanding Stocks Under $50 to Buy and Hold Now Nvidia's Bringing Sovereign AI to Germany. Should You Buy NVDA Stock Here? A $1 Billion Reason to Buy MicroStrategy Stock Here Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. The company is currently trading 1% below its 52-week high of $264.03 met on Jun. 16. LH shares have grown 9.1% over the past three months, outperforming the broader Dow Jones Industrial Average's ($DOWI) 1.4% rise during the same time frame. LH shares have surged 14% year-to-date, outperforming the Dow Jones Industrial Average's marginal pullback during the same period. Moreover, over the past 12 months, LH has delivered a solid 26.6% return, outpacing the Dow's 8.6% gain and showcasing its longer-term strength. To confirm its bullish trend, LH has been trading above its 200-day and 50-day moving averages since late April. LH shares rose 4.7% following the release of its Q1 earnings on Apr. 29. The company posted a revenue of $3.4 billion, falling behind the Street's estimates. Moreover, its adjusted EPS of $3.84 beat the consensus estimate by 3%, driven by 6% growth in its Diagnostics Laboratories business to $2.6 billion. Its peer, Natera, Inc. (NTRA) has grown 8% in 2025 and 58.3% over the past year, outperforming the stock. Among the 17 analysts covering the LH stock, the consensus rating is a 'Strong Buy.' Its mean price target of $277.24 suggests a modest 6.1% upside potential from current price levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Yahoo
16 hours ago
- Yahoo
Is J.B. Hunt Transport Stock Underperforming the S&P 500?
Lowell, Arkansas-based J.B. Hunt Transport Services, Inc. (JBHT) provides surface transportation, delivery, and logistics services in the United States. With a market cap of $13.8 billion, the company operates through five segments: Intermodal (JBI), Dedicated Contract Services (DCS), Integrated Capacity Solutions (ICS), Final Mile Services (FMS), and Truckload (JBT). Companies worth $10 billion or more are typically referred to as "large-cap stocks." JBHT fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the integrated freight & logistics industry. 2 Outstanding Stocks Under $50 to Buy and Hold Now Nvidia's Bringing Sovereign AI to Germany. Should You Buy NVDA Stock Here? A $1 Billion Reason to Buy MicroStrategy Stock Here Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Despite its strengths, the stock has dipped 30.6% from its 52-week high of $200.40 touched on Nov. 11, 2024. Moreover, over the past three months, JBHT stock has declined 5.5%, underperforming the S&P 500 Index's ($SPX) 5.4% uptick during the same time frame. JBHT stock has declined 18.6% on a YTD basis, underperforming SPX's 1.7% uptick in 2025. Moreover, JBHT has declined 10.7% over the past 52 weeks, underperforming SPX's 9% gains. JBHT stock has been trading below its 200-day moving average since mid-February and mostly above its 50-day moving average since mid-May. On Apr. 15, JBHT stock declined 2% following the release of its Q1 earnings. The trucking and logistics company posted revenue of $2.92 billion in the period, which met Street forecasts. Moreover, its adjusted earnings for the quarter amounted to $1.17, surpassing the consensus estimates by 1.7%. Within the integrated freight & logistics industry, rival Expeditors International of Washington, Inc. (EXPD) has grown 2.1% in 2025 and has declined 9.2% over the past year, slightly outperforming the stock. Among the 24 analysts covering the JBHT stock, the consensus rating is a 'Moderate Buy.' Its mean price target of $151.33 suggests a modest 8.9% upside potential from current price levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
